The press release highlighted two abstracts and upcoming [poster, presumably] presentations of results from the company's ongoing liver Phase 1 trial, which has evolved into (a) a "basket study" treating patients with and collecting data on a range of tumor types affecting the liver, and (b) a study of hepatocellular carcinoma (HCC) (primary liver cancer).
Results from patients with colorectal cancer that has metastasized to the liver, and treated with PV-10 (Rose Bengal) will be presented at the 2017 Symposium on Clinical Interventional Oncology (CIO) (CIO) on February 4-5 in Hollywood, Florida. These data should comprise results from at least 5 patients (see the slide from Provectus' November 14th 3Q16 business update call below). The title of the abstract is "Percutaneous Rose Bengal as an Ablative Immunotherapy for Hepatic Metastases," with my underlined emphasis.
Results from patients with HCC, and treated with PV-10 (Rose Bengal), the original goal or initial phase of the liver Phase 1 study, will be presented at the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL) on February 15-19 in Shanghai, China. These data should comprise results from the original/initial patients (see the slide below). The title of the abstract is "Intralesional Rose Bengal as an Ablative Immunotherapy for Hepatic Tumors," with my underlined emphasis.
|Click to enlarge.|
Initial liver data was presented in Barcelona, Spain and Osaka, Japan in July 2015, "Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver." Note the absence of the word "immunotherapy" in the abstract/poster's title.